Understanding Carvykti™

understanding carvykti cover

Carvykti™ (ciltacabtagene autoleucel, or “cilta-cel” for short) is a customized immunotherapy approved by the FDA for the treatment of adult patients with relapsed or refractory myeloma after four or more prior lines of therapy. Carvykti uses a patient’s own T cells, which are collected and genetically modified, then infused back into the patient. Carvykti works by recognizing and binding to BCMA, a protein on myeloma cells, leading to the destruction of BCMA-expressing cells, thereby eliminating the myeloma cells.


Source URL: https://www.myeloma.org/resource-library/understanding-carvykti